Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Physician Group Support Boosts OTC Contraception Chances

This article was originally published in The Tan Sheet

Executive Summary

The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics recommend OTC availability of hormonal contraception, but pharmaceutical industry Rx-to-OTC switch sponsors remain elusive.

You may also be interested in...



Potential OTC Contraception Market Could Attract Switch

A report showed 62.2% of 2,046 women surveyed favor OTC sales of contraception pills, representing a potential U.S. market of around 11 million. The results also could reflect consumer interest in making the drugs available OTC under conditions of safe use.

Potential OTC Contraception Market Could Attract Switch

A report showed 62.2% of 2,046 women surveyed favor OTC sales of contraception pills, representing a potential U.S. market of around 11 million. The results also could reflect consumer interest in making the drugs available OTC under conditions of safe use.

Potential OTC Contraception Market Could Attract Switch

A report showed 62.2% of 2,046 women surveyed favor OTC sales of contraception pills, representing a potential U.S. market of around 11 million. The results also could reflect consumer interest in making the drugs available OTC under conditions of safe use.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel